PDS Biotech shares surge 11.19% intraday on positive Phase 2 IL-12 immunocytokine trial results for prostate cancer.

PDS Biotechnology surged 11.19% intraday following the announcement of promising Phase 2 study results for its IL-12 immunocytokine, PDS01ADC. The trial, led by the National Cancer Institute, demonstrated a median progression-free survival of 9.6 months in prostate cancer patients and a 40% median PSA decline, presented at the AACR conference. These data underscore the therapy’s potential to enhance existing treatments and advance PDS01ADC in the company’s immuno-oncology pipeline. The timing aligns with the trading session, as the news was released on January 28, 2026, directly preceding the observed intraday price movement. Earlier news items, such as prior conference participations or buy ratings, were older and less directly linked to the immediate intraday rally.